The University of Edinburgh disclosed new benzoxazol mTOR (FRAP1) inhibitors, describing potential therapeutic use across cancer, autoimmune and inflammatory conditions, metabolic disease, fibrosis, parasitic infections, and neurological disorders. The patent disclosure indicates the university’s ongoing work to expand mTOR-targeted chemical matter. mTOR pathway inhibition remains a major mechanism class in oncology and immune regulation, but new chemotypes are still sought to improve properties such as potency, selectivity, and tolerability. The disclosure adds to the intellectual property landscape around FRAP1-directed small molecules and could feed into licensing or translational collaborations as compounds move toward preclinical profiling.